
The European Medicines Agency (EMA) published a positive opinion on the use of the dapivirine vaginal ring for women ages 18 and older in developing countries to reduce their risk of HIV-1 infection. The monthly ring is the first long-acting HIV prevention product and is designed to help address women’s unmet need for new prevention methods given the persistently high rates of HIV they face, especially in sub-Saharan Africa.